Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

BACKGROUND: Moderate‐to‐severe atopic dermatitis (AD) often requires long-term management with systemic therapies. OBJECTIVE: Our objective was to report the safety and efficacy of dupilumab treatment up to 4 years in adults with moderate-to-severe AD and efficacy in a subgroup of patients who trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, Lisa A., Deleuran, Mette, Bissonnette, Robert, de Bruin-Weller, Marjolein, Galus, Ryszard, Nakahara, Takeshi, Seo, Seong Jun, Khokhar, Faisal A., Vakil, Jignesh, Xiao, Jing, Marco, Ainara Rodriguez, Levit, Noah A., O’Malley, John T., Shabbir, Arsalan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063621/
https://www.ncbi.nlm.nih.gov/pubmed/35503163
http://dx.doi.org/10.1007/s40257-022-00685-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063621/
https://www.ncbi.nlm.nih.gov/pubmed/35503163
http://dx.doi.org/10.1007/s40257-022-00685-0

Ejemplares similares